Get the Stockscreener App
61.09
0.26%
0.20
Halozyme Therapeutics Inc stock is traded at $61.09, with a volume of 177.29K.
It is up +0.26% in the last 24 hours and up +4.16% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$60.89
Open:
$60.77
24h Volume:
177.29K
Relative Volume:
0.14
Market Cap:
$7.74B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
20.23
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+1.50%
1M Performance:
+4.16%
6M Performance:
-2.01%
1Y Performance:
+47.64%
1-Day Range:
$60.44
$61.34
1-Week Range:
$59.18
$63.11
52-Week Range:
$37.73
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
61.05 | 7.74B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.15 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.87 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.18 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.18 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.47 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Smartleaf Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why - MSN
New version of Merck's Keytruda faces possible patent battle, WSJ reports - MSN
Halozyme Therapeutics (NASDAQ:HALO) Earns Buy Rating from HC Wainwright - Defense World
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ - MSN
Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright maintains Halozyme stock Buy rating, $72 target By Investing.com - Investing.com Canada
High Growth Tech Stocks To Watch In US March 2025 - Yahoo Finance
JMP maintains Halozyme stock $78 target amid Merck challenge - Investing.com India
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Merck, Halozyme in patent battle over new Keytruda (MRK:NYSE) - Seeking Alpha
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Halozyme director Jeffrey Henderson sells shares worth $293,458 - Investing.com India
Halozyme Therapeutics Director Sells 5,000 Shares - TradingView
Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Principal Financial Group Inc. - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $98,901.16 in Stock - MarketBeat
Michael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock - MarketBeat
Los Angeles Capital Management LLC Has $4.42 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics SVP sells $1.26 million in stock By Investing.com - Investing.com Canada
Insider Sell Alert: Michael Labarre Sells Shares of Halozyme The - GuruFocus.com
Halozyme Therapeutics SVP sells shares totaling $1.26 million By Investing.com - Investing.com South Africa
Halozyme Therapeutics SVP sells $1.26 million in stock - Investing.com India
Halozyme Therapeutics SVP sells shares totaling $1.26 million - Investing.com
Halozyme Therapeutics Officer Sells Shares - TradingView
Halozyme Therapeutics (NASDAQ:HALO) Updates FY 2025 Earnings Guidance - MarketBeat
Private Advisor Group LLC Raises Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference - Citizentribune
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Principal Financial Group Inc. - Defense World
SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. converted options into 4,747 shares and covered exercise/tax liability with 2,410 shares, increasing direct ownership by 1% to 195,453 units (SEC Form 4) - Quantisnow
Halozyme Therapeutics’ (HALO) Buy Rating Reiterated at Benchmark - Defense World
Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products - MSN
Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
SEC Form 4 filed by SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole - Quantisnow
SEC Form 4 filed by PRESIDENT AND CEO Torley Helen - Quantisnow
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat
Hussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth - MSN
Meitav Investment House Ltd. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - Simply Wall St
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB - MarketBeat
Rhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts - Benzinga
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Halozyme Therapeutics Inc Stock (HALO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 26 '25 |
Sale |
58.12 |
10,000 |
581,244 |
175,453 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 25 '25 |
Sale |
58.05 |
10,000 |
580,534 |
185,453 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Feb 27 '25 |
Sale |
58.28 |
1,697 |
98,902 |
173,756 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):